PTC Therapeutics Inc banner

Intrinsic Value

The intrinsic value of PTC Therapeutics Inc (BH3) under the Base Case is 73.9 EUR per share. Compared with the current market price of 54.26 EUR, the stock appears Undervalued by 27% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

BH3 Intrinsic Value
€73.9
Undervaluation 27%
Intrinsic Value
Price €54.26
Alert me when BH3 is below its intrinsic value
Today €51.73 · 4.7% below the current price

BH3 is cheaper than usual. It was this cheap or cheaper on just 24% of days in the past 5 years.

Alternatives to BH3

Fundamental Analysis

What PTC Therapeutics Does

Biotechnology Health Care

PTC Therapeutics is a biotechnology company that focuses on medicines for rare diseases, especially inherited disorders that affect children and small patient groups. It develops drugs meant to treat the root cause of certain genetic conditions, then seeks approval to sell them in the United States and other markets. Its business is narrower than a big drugmaker’s: it concentrates on hard-to-treat diseases where patients have few other options.

Headquarters
United States of America US
Employees
991
IPO date
Jun 20, 2013
Read the full company overview
View Company Overview

PTC Therapeutics has a narrow economic moat

No Moat Narrow Wide

PTC Therapeutics Inc has a narrow economic moat, offering limited protection against competitors and some ability to sustain profitability.

Read the full moat analysis
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Latest Earnings Call

Q3 2026 · October 29, 2026

Sephience’s launch momentum supported a higher 2026 outlook, while the ST-920 acquisition added a near-term Fabry gene-therapy opportunity.

Open the earnings call
EPS
$0.61
Expected
$0.17
Surprise
+258.8%
Stock, next trading day
−7.0%
View Earnings Call

PTC Therapeutics insiders are selling more than usual

Insider trading · Last trade on Oct 14, 2026

Sold $24.1m 13 insiders
Bought $0 Nobody bought
Trades by date
Open insider trading

Insiders sell for many reasons, such as taxes or planned sales; purchases are rarer.

Past 12 months

Continue BH3 Research

Decided on PTC Therapeutics? Get an email when BH3 reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one BH3 stock?

The intrinsic value for PTC Therapeutics Inc (BH3) under the Base Case is 73.9 EUR.

Is BH3 stock undervalued or overvalued?

Compared with the current market price of 54.26 EUR, the stock appears Undervalued by 27% .

How reliable are our estimates? See how past valuations played out
Back to Top